SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
|Date of Report (Date of earliest event reported)
||November 29, 2012|
|ProUroCare Medical Inc.|
|(Exact name of registrant as specified in its charter)|
|(State or other jurisdiction
|6440 Flying Cloud Dr., STE 101, Eden Prairie, MN
|(Address of principal executive offices)
|Registrant’s telephone number, including area code
|(Former name or former address, if changed since last report.)|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Item 1.01 Entry into Material
On November 29, 2012,
ProUroCare Medical Inc. (the “Company”) amended the maturity date of its $900,000 promissory note with Crown Bank (the
“Crown Loan”). The maturity date was changed to December 31, 2012. The outstanding principal balance due on the note
is $500,000. There were no other changes made in the terms of the Crown Loan. The Crown Loan remains secured by all
Company assets and continues to be guaranteed by James L. Davis, a director of the Company and William S. Reiling. The amendment
is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03 Creation of a Direct
Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of the Company
The information under Item
1.01 above is incorporated herein by reference.
Item 8.01 Other Events
On November 30, 2012,
the Company announced that that current director Dr. Michael Chambers, JD, Ph.D., has been named Chairman of its Board of Directors.
Dr. Chambers assumes the Chairmanship role from Rick Carlson, ProUroCare’s CEO, who will continue to serve as CEO and Director.
A copy of the Company’s
announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
|10.1||Modification to Promissory Note issued in favor of Crown Bank, Dated November 30, 2012 (filed herewith).|
|99.1||Announcement of naming of Michael Chambers as Chairman of ProUroCare Medical Inc.’s Board of
Directors, dated November 30, 2012 (filed herewith).|
Pursuant to the requirements of the Securities
and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
||PROUROCARE MEDICAL INC.|
|November 30, 2012
||/s/ Richard C. Carlson|
||Richard C. Carlson|
||Chief Executive Officer|